RCKT - イノテック・ファ―マシュ―ティカルズ (Rocket Pharmaceuticals Inc.)

RCKTのニュース

   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private  2020/08/12 11:08:59 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Burning Rock Biotech Ltd (NASDAQ: BNR )(announced its second-quarter results) Homology Medicines Inc (NASDAQ: FIXX )(reacted to its second-quarter results) Legend Biotech Corp (NASDAQ: LEGN ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Stocks In Focus Moderna Clinches Deal With U.S.
   The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September  2020/08/11 12:20:27 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical readout) Silk Road Medical Inc (NASDAQ: SILK ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) (announced FDA nod for pain drug) Unity Biotechnology Inc (NASDAQ: UBX ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 10) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) (went public Friday) Freeline Therapeutics Holdings plc ADS (NASDAQ: FRLN ) (went public Friday) Lantern Pharma Inc. (NASDAQ: LTRN ) Nkarta Inc (NASDAQ: NKTX ) Recro Pharma Inc (NASDAQ: REPH ) (reacted to second-quarter results) Stocks In Focus Equillium Announces Positive Interim Data For Lead Drug, Requests Pre-IND Meeting For COVID-19 Study Equillium Inc (NASDAQ: EQ ) announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease.
   Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis  2020/06/29 11:00:00 Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis  2020/06/29 11:00:00 Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?  2020/04/09 12:22:00 Zacks Investment Research
Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I  2019/12/09 12:00:00 Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
   Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis  2020/06/29 11:00:00 Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?  2020/04/09 12:22:00 Zacks Investment Research
Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I  2019/12/09 12:00:00 Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies

calendar